Business Context and Reporting Period
DarioHealth Corp. (DRIO) filed this Form 8-K on December 6, 2019, reporting events occurring between December 3 and December 5, 2019. The filing details the closing of a multi-stage private equity offering involving the sale of newly designated Series A-2, A-3, and A-4 Preferred Stock to accredited investors.
Key Financial Metrics
The Company raised aggregate gross proceeds of $6.468 million from the specific offerings detailed in this report (Series A-2, A-3, and A-4). When combined with proceeds from Series A and Series A-1 Preferred Stock closed on November 27, 2019, the total gross proceeds for the entire Offering series reached $20.029 million.
- Series A-2 Proceeds: $1.915 million (1,915 shares at $1,000/share).
- Series A-3 Proceeds: $3.808 million (3,808 shares at $1,000/share).
- Series A-4 Proceeds: $0.745 million (745 shares at $1,000/share).
- Placement Agent Fees: $599,800 cash fee plus $194,040 non-accountable expense allowance.
- Placement Agent Warrants: Issuance of warrants to purchase 194,326 shares of Common Stock at exercise prices ranging from $4.28 to $5.90.
The filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the capitalization structure resulting from the issuance of 6,468 shares of Preferred Stock. The Company filed Certificates of Designation for Series A-2, A-3, and A-4 Preferred Stock with the Delaware Secretary of State. These securities carry specific conversion rights, dividend rights payable in Common Stock, and voting rights on an as-converted basis.
Outlook, Risks, and Unusual Items
Conversion and Dividend Terms: The Preferred Stock is convertible into Common Stock at initial prices of $4.28 (Series A-2), $4.98 (Series A-3), and $5.90 (Series A-4). Automatic conversion occurs upon the earliest of shareholder approval (50.1% of respective series) or the 36-month anniversary of the effective dates. Holders are entitled to dividends in Common Stock equal to 10%, 15%, and 20% of the issuable shares upon conversion at the 12, 24, and 36-month anniversaries, respectively.
Registration Rights: The Company agreed to file a registration statement for the resale of Common Stock issuable upon conversion within 60 days of the final closing.
Risks and Contingencies: The securities were issued pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and are not registered. They may not be resold in the United States absent registration or an exemption. The filing explicitly states that representations and warranties in the Subscription Agreements are not for the benefit of the public.
Investor Verification Checklist
- Verify the total dilution impact of the 6,468 Preferred Shares and the 194,326 Placement Agent Warrants upon conversion.
- Confirm the Company's cash runway post-offering, as the filing does not disclose current cash balances or burn rate.
- Review the full text of the Certificates of Designation (Exhibits 3.1, 3.2, 3.3) for specific beneficial ownership limitations on conversion.
- Monitor the filing of the registration statement for resale of shares, required within 60 days of the final closing.
- Assess the impact of the dividend structure (10-20% of conversion shares) on future equity dilution.